Efficacy of fumaric acid ester monotherapy in psoriasis pustulosa palmoplantaris

Ständer, Hartmut; Stadelmann, Andreas M.; Luger, Thomas A.; Traupe, Heiko

doi:10.1046/j.1365-2133.2003.05424.x

Cited by 11 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A prospective, open label study showed good effects of FAE in improving psoriasis pustulosa palmoplantaris. 124 In addition, there was a case report of improvement of psoriasis pustulosa generalisata in a 55-year-old female patient. 125 There has been a small RCT of FAE in the treatment of psoriatic arthritis, in which minimal improvement of the arthritis was reported.…”

Section: Resultsmentioning

confidence: 99%

Fumaric acid esters in the management of psoriasis

Balak

2015

PTT

View full text Add to dashboard Cite

Fumaric acid esters (FAE) are small molecules with immunomodulating, anti-inflammatory, and anti-oxidative effects. FAE were introduced as a systemic psoriasis treatment in 1959 and empirically developed further between 1970 and 1990 in Germany, Switzerland, and the Netherlands. The development of FAE as psoriasis treatment did not follow the traditional drug development phases. Nonetheless, in 1994 FAE were approved in Germany for the treatment of severe plaque psoriasis. FAE are currently one of the most commonly used treatments in Germany, and FAE are increasingly being used as an unlicensed treatment in several other European countries. To date, six randomized controlled trials and 29 observational studies have evaluated FAE in a combined total of 3,439 patients. The efficacy and safety profile of FAE is favorable. About 50%–70% of patients achieve at least 75% improvement in psoriasis severity after 16 weeks of treatment. Common adverse events of FAE include gastrointestinal complaints and flushing symptoms, which lead to treatment discontinuation in up to 40% of patients. Lymphocytopenia, eosinophilia, and proteinuria are commonly observed during FAE treatment, but rarely require treatment discontinuation. The long-term safety profile of continuous FAE treatment is favorable without an increased risk for infections, malignancies, or other serious adverse events. There are no known drug-interactions for FAE. The 2009 European evidence-based S3-guidelines on psoriasis treatment recommend FAE and suggest it as a first-line systemic treatment for moderate-to-severe plaque psoriasis. This review is aimed to give an overview of FAE treatment in the management of psoriasis.

show abstract

Section: Resultsmentioning

confidence: 99%

Fumaric acid esters in the management of psoriasis

Balak

2015

PTT

View full text Add to dashboard Cite

show abstract

“…Early studies reporting their efficacy and safety 23 were followed by double‐blind studies supporting their superiority to placebo 24,25 . There are also reports of the efficacy of FAE in PPP 26 . Professor Tanew reported an investigator‐blinded head‐to‐head study comparing the short‐ and long‐term efficacy of FAE plus PUVA with acitretin plus PUVA.…”

Section: Combination Of Systemic Agents Including Biologics With Photmentioning

confidence: 99%

“…24,25 There are also reports of the efficacy of FAE in PPP. 26 Professor Tanew reported an investigator-blinded head-to-head study compar-ing the short-and long-term efficacy of FAE plus PUVA with acitretin plus PUVA. The study was divided into a clearing phase (up to 14 weeks), where patients were allocated to either acitretin (1 mg kg )1 daily) or FAE (up to 720 mg daily), a maintenance phase (24 weeks) and a follow-up phase (24 weeks).…”

Section: Combination Of Systemic Agents Including Biologics With Photmentioning

confidence: 99%

Psoriasis: an evidence-based update. Report of the 9th Evidenced Based Update Meeting, 12 May 2011, Loughborough, U.K.

Mozzi

Johnston

Alexandroff

2012

British Journal of Dermatology

View full text Add to dashboard Cite

The Centre of Evidence Based Dermatology, University of Nottingham, U.K. holds an annual Evidence Based Update (EBU) Meeting focused on important dermatological topics, which have in the past included eczema, urticaria, blistering disorders, skin infections, skin cancer and hair disorders. These one-day meetings aim to summarize the most recent evidence in the form of systematic reviews and recently completed clinical trials. This year, the 9th EBU meeting took place in Loughborough, U.K. on 12 May 2011 and was devoted to psoriasis. The latest updates on topical treatments, nail psoriasis, genetics and clinical implications, rational use of biologics, new and unpublished studies on combination of phototherapy and biologics for psoriasis, and on treatments of palmoplantar pustular psoriasis were discussed by a panel of renowned international speakers.

show abstract

“…Case reports demonstrate a beneficial effect of FAE on nail psoriasis or pustular psoriasis in some patients. [3239–41]…”

Section: Fumaric Acid Esters For Psoriasismentioning

confidence: 99%

Fumaric acid esters in dermatology

Wollina¹

2011

Indian Dermatol Online J

View full text Add to dashboard Cite

Fumaric acid esters (FAE) are substances of interest in dermatology. FAE exert various activities on cutaneous cells and cytokine networks. So far only a mixture of dimethylfumarate (DMF) and three salts of monoethylfumarate (MEF) have gained approval for the oral treatment of moderate-to-severe plaque-type psoriasis in Germany. DMF seems to be the major active component. There is evidence that FAE are not only effective and safe in psoriasis but granulomatous non-infectious diseases like granuloma annulare, necrobiosis lipoidica and sarcoidosis. In vitro and animal studies suggest some activity in malignant melanoma as well.

show abstract

Efficacy of fumaric acid ester monotherapy in psoriasis pustulosa palmoplantaris

Cited by 11 publications

References 10 publications

Fumaric acid esters in the management of psoriasis

Fumaric acid esters in the management of psoriasis

Psoriasis: an evidence-based update. Report of the 9th Evidenced Based Update Meeting, 12 May 2011, Loughborough, U.K.

Fumaric acid esters in dermatology

Contact Info

Product

Resources

About